Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So here’s our catalyst we’ve been waiting for!!!! Merck is proving that it works but they have pretty bad side effects. Bellus has comparable results with very low side effects. Enjoy: https://www.merck.com/news/mercks-gefapixant-45-mg-twice-daily-significantly-decreased-cough-frequency-compared-to-placebo-at-week-12-and-24-in-patients-with-refractory-or-unexplained-chronic-cough/
It would be great news but this company is Bellus. Who in the world is Bluth?
I am extremely confused but hopefully I am wrong about your opinion. In the corporate update, each one of the bullet points explain why the drug is dead in the water. The last bullet point clearly innuendos that they are either going to rm or purchase an asset to develop.
Can you please do me a huge favor and dissect the bullet points below and explain how you pull any possible way that you see a way forward for their hgh drug??? Further more I cannot imagine Teijin releasing their interest if there was any way possible for a future. Please advise.
Corporate Update
Based on a full review of the data from the Phase 3 VELOCITY trial, feedback from the FDA during the development of somavaratan, and an objective assessment by external regulatory experts, the company believes it could not successfully file for approval based on the existing dataset.
All current clinical trials of somavaratan have been concluded and the U.S. Investigational New Drug Application (IND) and equivalent filings in other countries have been withdrawn. Additionally, in January 2018, Teijin Limited (Teijin) terminated its license agreement for somavaratan in Japan following its evaluation of the VELOCITY trial results.
The investment and delay in time-to-market that further development would require significantly impact the business case for somavaratan, given the potential that one or more long-acting growth hormone products may already be commercialized for pediatric growth hormone deficiency during that time.
The company is focused on evaluating strategic opportunities to leverage its expertise and resources to create value for shareholders. Cowen is assisting the company in reviewing possible transactions, including strategic combinations and opportunities to diversify the Versartis pipeline.
Ummm—the 8k was released after hours yesterday. Will be interested to see what happens today. I am a bull so hopefully it is a non event.
$TTPH CFO hauls ass today “On February 21, 2018 Kamalam Unninayar resigned her position as chief financial officer of the Company”. Not good!!!!!!!!!
Thanks for the inquiry. I have been trying to get an answer from them for weeks. Sounds like we will be getting an update any day now. Hopefully it will be worth all of our time!!!!
What are some your picks besides Vsar with exploring alternatives?
Excellent hypothesis. I get the feeling that we will be finding out within the next three months.
Haha—my exact thoughts. Timing is everything in the stock market and sometimes it’s out of your control. Either going to be some extremely lucky buyers or some exceedingly lucky sellers. Time will tell my friend!!!!
Could be wrong but it might be the Re balancing of the biotech index. The time frame jives: https://seekingalpha.com/amp/news/3317422-nasdaq-biotech-index-54-added-15-removed
The first paragraph from your link:
What is 'Insider Trading'
Insider trading is the buying or selling of a security by someone who has access to material nonpublic information about the security. Insider trading can be illegal or legal depending on when the insider makes the trade. “It is illegal when the material information is still nonpublic.”
If a buyout, reverse merger or extremely positive safety data isn’t “material information that is still non public” I cannot imagine what inside information looks like.
Martha Stewart went to prison over a $45k tip. If this doubled on favorable information — the insider in this case would pocket a couple million off of “material information that is still non public”.
I am an investor in this company and would love to have this type of “inside information”. I don’t and therefore am not an insider that is trading on insider information.
Make sense??
Should mean jail but you are absolutely correct—99 percent of the time it means nothing.
Great news is that the insider is buying and not selling. Bad news is that nothing can happen too quickly at this point or he is going to jail for insider trading. I suspect we are a month or two out before news at this point.
So what do you think about the CFO leaving?? That is the major piece of the puzzle that I can’t understand. If there is a RM happening (or a buyout for that matter) the CFO is the most important part of the transaction. Further confusion is caused by the fact that if you read his departure compensation package-he received the full golden parachute that was an incentive to stay. Just not adding up right now. Your thoughts?? Must be pretty bullish with such a huge purchase.
I agree but the real question is: will a R/M be good for existing share holders?? I have only been through one but it was not good for existing. Do you know of any good ones??
How are we sitting from a technical standpoint??
I hope that you are right!!!!
Head fake or too early to tell??
Thanks--you keep nailing the TA!!
What is your new target re entry?